|
1
|
Global Burden of Disease Cancer
Collaboration, ; Fitzmaurice C, Dicker D, Pain A, Hamavid H,
Moradi-Lakeh M, MacIntyre MF, Allen C, Hansen G, Woodbrook R, et
al: The global burden of cancer 2013. JAMA Oncol. 1:505–527. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eyking A, Reis H, Frank M, Gerken G,
Schmid KW and Cario E: miR-205 and miR-373 are associated with
aggressive human mucinous colorectal cancer. PLoS One.
11:e01568712016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Compton CC: Colorectal carcinoma:
Diagnostic, prognostic, and molecular features. Mod Pathol.
16:376–388. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lai WG, Farah N, Moniz GA and Wong YN: A
Baeyer-Villiger oxidation specifically catalyzed by human
flavin-containing monooxygenase 5. Drug Metab Dispos. 39:61–70.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Siddens LK, Krueger SK, Henderson MC and
Williams DE: Mammalian flavin-containing monooxygenase (FMO) as a
source of hydrogen peroxide. Biochem Pharmacol. 89:141–147. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Henderson MC, Siddens LK, Krueger SK,
Stevens JF, Kedzie K, Fang WK, Heidelbaugh T, Nguyen P, Chow K,
Garst M, et al: Flavin-containing monooxygenase S-oxygenation of a
series of thioureas and thiones. Toxicol Appl Pharmacol. 278:91–99.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Biéche I, Girault I, Urbain E, Tozlu S and
Lidereau R: Relationship between intratumoral expression of genes
coding for xenobiotic-metabolizing enzymes and benefit from
adjuvant tamoxifen in estrogen receptor alpha-positive
postmenopausal breast carcinoma. Breast Cancer Res. 6:R252–R263.
2004. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Miller MM, James RA, Richer JK, Gordon DF,
Wood WM and Horwitz KB: Progesterone regulated expression of
flavin-containing monooxygenase 5 by the B-isoform of progesterone
receptors: Implications for tamoxifen carcinogenicity. J Clin
Endocrinol Metab. 82:2956–2961. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wang GH, Yao L, Xu HW, Tang WT, Fu JH, Hu
XF, Cui L and Xu XM: Identification of MXRA5 as a novel biomarker
in colorectal cancer. Oncol Lett. 5:544–548. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Cai C, Chen JY, Han ZD, He HC, Chen JH,
Chen YR, Yang SB, Wu YD, Zeng YR, Zou J, et al: Down-regulation of
dual-specificity phosphatase 5 predicts poor prognosis of patients
with prostate cancer. Int J Clin Exp Med. 8:4186–4194.
2015.PubMed/NCBI
|
|
11
|
Pettit FH, Orme-Johnson W and Ziegler DM:
The requirement for flavin adenine dinucleotide by a liver
microsmal oxygenase catalyzing the oxidation of alkylaryl amines.
Biochem Biophys Res Commun. 16:444–448. 1964. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Uetrecht J and Trager W: Drug metabolism
chemical and enzymatic aspects. New York: Crc Press; 2007,
View Article : Google Scholar
|
|
13
|
Zhang J and Cashman JR: Quantitative
analysis of FMO gene mRNA levels in human tissues. Drug Metab
Dispos. 34:19–26. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krueger SK and Williams DE: Mammalian
flavin-containing monooxygenases: Structure/function, genetic
polymorphisms and role in drug metabolism. Pharmacol Ther.
106:357–387. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Janmohamed A, Hernandez D, Phillips IR and
Shephard EA: Cell-, tissue-, sex- and developmental stage-specific
expression of mouse flavin-containing monooxygenases (Fmos).
Biochem Pharmacol. 68:73–83. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Cashman JR and Zhang J: Human
flavin-containing monooxygenases. Annu Rev Pharmacol Toxicol.
46:65–100. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Gonzalez Malagon SG, Melidoni AN,
Hernandez D, Omar BA, Houseman L, Veeravalli S, Scott F, Varshavi
D, Everett J, Tsuchiya Y, et al: The phenotype of a knockout mouse
identifies flavin-containing monooxygenase 5 (FMO5) as a regulator
of metabolic ageing. Biochem Pharmacol. 96:267–277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Cerny MA, Lawson M, Mosadeghi R
and Cashman JR: Functional activity of the mouse flavin-containing
monooxygenase forms 1, 3 and 5. J Biochem Mol Toxicol. 21:206–215.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Motika MS, Zhang J, Ralph EC, Dwyer MA and
Cashman JR: pH dependence on functional activity of human and mouse
flavin-containing monooxygenase 5. Biochem Pharmacol. 83:962–968.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lang DH, Yeung CK, Peter RM, Ibarra C,
Gasser R, Itagaki K, Philpot RM and Rettie AE: Isoform specificity
of trimethylamine N-oxygenation by human flavin-containing
monooxygenase (FMO) and P450 enzymes: Selective catalysis by FMO3.
Biochem Pharmacol. 56:1005–1012. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ohmi N, Yoshida H, Endo H, Hasegawa M,
Akimoto M and Higuchi S: S-oxidation of S-methyl-esonarimod by
flavin-containing monooxygenases in human liver microsomes.
Xenobiotica. 33:1221–1231. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Rae JM, Johnson MD, Lippman ME and
Flockhart DA: Rifampin is a selective, pleiotropic inducer of drug
metabolism genes in human hepatocytes: Studies with cDNA and
oligonucleotide expression arrays. J Pharmacol Exp Ther.
299:849–857. 2001.PubMed/NCBI
|
|
23
|
Krusekopf S and Roots I: St. John's wort
and its constituent hyperforin concordantly regulate expression of
genes encoding enzymes involved in basic cellular pathways.
Pharmacogenet Genomics. 15:817–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Overby LH, Carver GC and Philpot RM:
Quantitation and kinetic properties of hepatic microsomal and
recombinant flavin-containing monooxygenases 3 and 5 from humans.
Chem Biol Interact. 106:29–45. 1997. View Article : Google Scholar : PubMed/NCBI
|
